von Pawel J, et al. - Based on OAK, a randomized, phase 3 trial that exhibited significantly better survival with atezolizumab (anti–programmed death-ligand 1 [PD-L1]) vs docetaxel irrespective of PD-L1 expression, the US Food and Drug Administration and European Medicines Agency approved atezolizumab for previously treated advanced non–small-cell lung cancer. Researchers conducted a longer follow-up to summarize the traits of long-term survivors (LTSs). Patients who lived ≥24 months since randomization were defined as LTSs. After >2 years of follow-up, durable survival benefit remained evident with atezolizumab vs docetaxel, with tolerable safety. Atezolizumab-arm LTSs were enriched for patients with high PD-L1 expression and included PD-L1–negative patients. Long-term survival was not limited to patients who responded.